Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream

Reuters

2025/07/22

Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream

Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize $(ABC.AU)$ strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553709253"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553709253\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553709253?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553709253","market":"fut","top_or_hot":-1,"title":"Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by <a href=\"https://laohu8.com/S/WSCO\">Wall Street</a> Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize <a href=\"https://laohu8.com/S/ABC.AU\">$(ABC.AU)$</a> strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-22 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by <a href=\"https://laohu8.com/S/WSCO\">Wall Street</a> Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize <a href=\"https://laohu8.com/S/ABC.AU\">$(ABC.AU)$</a> strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL1Bh3Sd:1","article_id":"2553709253","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553709253","pubTimestamp":1753186525,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aditxt, Inc.  recently highlighted the innovations of its wholly owned subsidiary, Adimune, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize  strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ADTX":"ADiTx Therapeutics"},"translate_title":"阿迪穆尼™占据中心舞台：Aditxt子公司在即将到来的直播中瞄准自身免疫性突破","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADTX":0.9},"content_text":"Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    \n\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize $(ABC.AU)$ strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}